日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Spi-1 proto-oncogene regulates mRNA hypertranscription and malignant progression in head and neck cancer

Spi-1原癌基因调控头颈癌中的mRNA过度转录和恶性进展

Liu, Zheran; Qin, Zijian; Li, Huilin; Zhu, Lili; He, Ling; Chen, Na; Zhu, Dan; Liu, Qinghong; Dai, Lei; Peng, Xingchen

lncRNA-based prognostic model for pancreatic cancer centered on the TME with exploratory LLPS connections

基于lncRNA的胰腺癌预后模型,以肿瘤微环境(TME)为中心,探索LLPS关联

Wei, Yaqing; Sun, Xiguang; Ding, Changjun; Wang, Yifei; Lu, Zheran; Zhang, Chenhui; Yao, Hao; Huang, Hao

Biomimetic Hierarchical Construction of Anti-Tumor Polyoxopalladates for Cancer Therapy

仿生分层构建抗肿瘤多氧钯酸盐用于癌症治疗

Zhao, Yue; Liu, Zheran; Qin, Zijian; Wen, Qinlong; Du, Jing; Ren, Xiang-Yu; Chen, Chao-Qin; Peng, Xingchen; Kortz, Ulrich; Yang, Peng

Multidisciplinary Team Support for Patients With Head and Neck Cancer Receiving Radiotherapy: A Randomized Clinical Trial

为接受放射治疗的头颈癌患者提供多学科团队支持:一项随机临床试验

Pei, Yiyan; Wang, Jingjing; Li, Juejin; Chen, Ye; He, Jinlan; Wei, Zhigong; Liu, Zheran; Su, Yonglin; Dai, Tingting; Yin, Li; Deng, Yaotiao; Zhou, Jitao; Tian, Hangrui; Li, Yunhuan; Chen, Xiaoli; Zhang, Shu; Chen, Yang; Yan, Qianwen; Li, Ruidan; Jiang, Zheng; Hu, Xiaolin; Peng, Xingchen

Summary of the 2024 report on gastroenterology and digestive endoscopy in China

中国2024年胃肠病学和消化内镜报告摘要

Chen, Zheran; Xu, Yusi; Xin, Lei; Song, Yifei; Xu, Jinfang; Chu, Chu; Yu, Chuting; Gao, Ye; Ma, Xudong; Li, Zhaoshen; Wang, Luowei

Editorial: Opportunities and challenges of head and neck cancer treatment in the era of immune checkpoint inhibitors

社论:免疫检查点抑制剂时代头颈癌治疗的机遇与挑战

Liu, Zheran; Cai, Lei; Peng, Xingchen

Correction: Association between statin use and immune-related adverse events in patients treated with immune checkpoint inhibitors: analysis of the FAERS database

更正:他汀类药物使用与接受免疫检查点抑制剂治疗的患者发生免疫相关不良事件之间的关联:FAERS数据库分析

Yang, Huaju; Huang, Rendong; Zhang, Ping; Liu, Yingtong; Liu, Zheran; He, Jiagang; Peng, Xingchen

Association of type 2 diabetes, hypertension, and hyperlipidemia with immune-related adverse events in patients undergoing immune checkpoint inhibitors therapy

2型糖尿病、高血压和高脂血症与接受免疫检查点抑制剂治疗的患者发生免疫相关不良事件的关联

Li, Ruidan; Mu, Xiaoli; Liu, Zheran; Huang, Rendong; Peng, Xingchen

Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)

基线转移部位作为 PD-L1 抑制剂治疗复发或转移性鼻咽癌的预测因子:多中心、单臂、II 期研究 (KL-A167) 的二次分析

Li, Yuantai; Min, Yu; Wei, Zhigong; Liu, Zheran; Pei, Yiyan; Yang, Yujie; Gao, Kun; Song, Ge; Xu, Shihong; He, Shuangshuang; Ge, Junyou; Qing, Yan; Wei, Youneng; Ai, Ping; Chen, Ye; Peng, Xingchen

Correction: Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)

更正:基线转移部位作为 PD-L1 抑制剂治疗复发或转移性鼻咽癌的预测因子:多中心、单臂、II 期研究 (KL-A167) 的二次分析

Li, Yuantai; Min, Yu; Wei, Zhigong; Liu, Zheran; Pei, Yiyan; Yang, Yujie; Gao, Kun; Song, Ge; Xu, Shihong; He, Shuangshuang; Ge, Junyou; Qing, Yan; Wei, Youneng; Ai, Ping; Chen, Ye; Peng, Xingchen